2. Signaling Pathways
  3. JAK/STAT Signaling
  4. Pim
  5. PIM2 Isoform

PIM2

PIM2 is a serine/threonine kinase that supports cell survival and proliferation, and early work defined Pim-2 as a transcriptionally regulated apoptotic inhibitor[1]. Mechanistically, PIM2 phosphorylates BAD at Ser112 and reverses BAD-induced cell death, linking PIM2 kinase activity to anti-apoptotic signaling[2]. In multiple myeloma, Pim2 expression is highly elevated and is required for myeloma cell proliferation through TSC2 phosphorylation and mTORC1 modulation[3]. PIM2 kinase also supports plasmablast generation and plasma cell survival, connecting B-cell differentiation models with myeloma research applications[4]. Compared with related isoforms, PIM2 shares 55% sequence identity with PIM1, but structural differences between PIM1 and PIM2 may guide isoform-selective inhibitor design[5]. In BAD phosphorylation assays, Pim-2 predominantly phosphorylated Ser112, whereas Pim-3 was least specific for Ser112 and more effective at Ser136 and Ser155[6]. For experimental applications, the pan-PIM inhibitor PIM447 showed preclinical antimyeloma and bone-protective effects, while first-in-human studies evaluated oral PIM447 in relapsed or refractory multiple myeloma[7][8].

PIM2 관련 제품 (29):

Cat. No. 상품명 효과 Purity
  • HY-123983
    HS56
    		Inhibitor 99.6%
    HS56 is an ATP-competitive dual Pim/DAPK3 inhibitor with Ki values of 0.26, 0.208, 2.94, and ＞100 μM for DAPK3, Pim-3, Pim-1, and Pim-2, respectively. HS56 inhibits LC20 phosphorylation and smooth muscle contraction. HS56 decreases blood pressure in spontaneously hypertensive mice. HS56 can be used in research of hypertension.
  • HY-142696
    CDK6/PIM1-IN-1
    		Inhibitor
    CDK6/PIM1-IN-1 is a potent and balanced dual CDK6/PIM1 inhibitor with IC50 values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC50=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity.
  • HY-101783
    GNE-955
    		Inhibitor
    GNE-955 is a potent and orally active pan Pim kinase inhibitor with Kis of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively.
  • HY-168479
    VB1080
    		Inhibitor
    VB1080 (compound 12) is a potent PIM inhibitor with IC50 values of 69.5, 4996, 9.88 µM for PIM1, PIM2, PIM3, respectively. VB1080 shows cytotoxicity. VB1080 shows anthelmintic activity.
  • HY-163119
    Pim-1 kinase inhibitor 9
    		Inhibitor
    Pim-1 kinase inhibitor 9 (compound 8b) is a selective inhibitor against Pim-1 kinase with IC50 value of 0.24 µM. Pim-1 kinase inhibitor 9 inhibits cell cycle of T47D at S phase. Pim-1 kinase inhibitor 9 reveals antitumor activity.
  • HY-160006
    PIM-IN-2
    PIM-IN-2 (Pim-2) is a Pim kinases inhibitor (IC50 = 25 nM). PIM-IN-2 promotes cell survival, is antiapoptotic, and has exhibited an elevated level of expression in a variety of human tumors.
  • HY-15698B
    CRT0066101 trihydrochloride
    		Inhibitor
    CRT0066101 trihydrochloride is the trihydrochloride salt form of CRT0066101 (HY-15698). CRT0066101 trihydrochloride is an orally active PKD inhibitor with IC50 values of 1 nM, 2.5 nM and 2 nM for PKD1, PKD2, and PKD3, respectively. CRT0066101 trihydrochloride is also an inhibitor for PIM2 with an IC50 of ~135.7 nM. CRT0066101 trihydrochloride exhibits anti-inflammatory activity in mice LPS (HY-D1056)-induced lung injury models, and has anticancer effects.
  • HY-163442A
    PIM3-IN-1 hydrochloride
    		Inhibitor
    PIM3-IN-1 hydrochloride (Compound 19a) is an inhibitor of (PIM2/3), with the highest inhibition level being against PIM3, having an IC50 value in the nanomolar range. PIM3-IN-1 hydrochloride can be used in cancer research.
  • HY-157404
    Pim-1/2 kinase inhibitor 2
    		Inhibitor
    Pim-1/2 kinase inhibitor 2 (compound 5b) is a competitive PIM-1 and PIM-2 kinase inhibitor with IC50s of 1.31 μM and 0.67 μM, respectively. Pim-1/2 kinase inhibitor 2 shows in-vitro low cytotoxicity against normal human lung fibroblast Wi-38 cell line and potent in-vitro anticancer activity against myeloid leukaemia (NFS-60), liver (HepG-2), prostate (PC-3), and colon (Caco-2) cancer cell lines.